Clinical Trial News

The U.S. Food and Drug Administration (FDA) recently approved TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). TALZENNA is the first and only PARP inhibitor approved for use with an existing standard of care (XTANDI) for adult patients with this condition. The FDA’s approval of the combination […]